Table 1.
Demographic, comorbidity, and SLE disease characteristics and therapies before SARS-CoV-2 vaccination.
| Demographics | |
|---|---|
| Age, years, median (IQR) | 48 (35–56) |
| Disease duration, months, median (IQR) | 128 (73,75–197,25) |
| Female, n (%) | 417 (92.25) |
| Laboratory, median (25th–75th) | |
| ESR, mm/h + | 13 (7–21) |
| CRP, mg/dL | 0.5 (0.29–0.51) |
| IgG, mg/dL £ | 1138 (882.5–1405) |
| Serology and organ involvement ever, n (%) | |
| Anti-dsDNA positivity § | 382 (85) |
| Anti-Sm positivity $ | 48 (11) |
| Low complement (C3 and/or C4) | 159 (35) |
| Musculoskeletal involvement | 382 (85) |
| Mucocutaneus involvement | 294 (65) |
| Renal involvement | 224 (50) |
| Urinary abnormalities | 84 (19) |
| NPSLE involvement | 46 (10) |
| Cardiopulmonary involvement | 93 (21) |
| Haematological involvement | 149 (33) |
| Constitutional symptoms | 158 (35) |
| Gastrointestinal involvement | 16 (4) |
| Ophthalmic involvement | 12 (3) |
| Anti-phospholipid antibodies positivity | 142 (31) |
| Secondary anti-phospholipid syndrome | 48 (11) |
| Therapy, n (%) | |
| No therapy | 12 (3) |
| Hydroxychloroquine | 374 (83) |
| Prednisone | 322 (71) |
| Immunosuppressor * | 228 (50) |
| Cyclophosphamide ever | 112 (25) |
| Rituximab ever | 59 (13) |
| Disease activity before SARS-CoV-2 vaccination, n (%) | |
| Remission/LLDAS | 402 (89) |
| Moderate/High DAS | 50 (11) |
| SARS-CoV-2 infection, n (%) | |
| Infection before vaccination | 13 (3) |
| Infection after vaccination | 77 (17) |
+ not available for 3 patients. £ not available for 286 patients. § not available for 17 patients. $ not available for 1 patient. * Azathioprine, mycophenolate, belimumab, cyclophosphamide, leflunomide, adalimumab, rituximab, tocilizumab, tacrolimus. IQR: interquartile range. ESR: erythrocyte sedimentation rate. CRP: C-reactive protein. NPSLE: neuropsychiatric involvement in systemic lupus erythematosus. LLDAS: lupus low disease activity score, DAS: disease activity score.